arXiv Science⌕ Search

arXiv · 2610.33195

Agent-guided epitope excision enables economical de novo binder design

Abstract

De novo protein design campaigns remain bottlenecked by the inference compute time required to generate and rank candidates, limiting wider functional exploration. Here, we introduce and evaluate an epitope excision approach that truncates targets to local interface windows to accelerate both backbone diffusion and structure prediction. Across 15 targets and 3,666 designs, excised windows closely reproduced full-target binding interfaces (median CαRMSD of 0.37 Å) and made it practical to design binders against the 719-residue extracellular domain of fibroblast activation protein alpha (FAP) by cutting RFdiffusion and AlphaFold3 GPU time by ~ 88% in one of the epitopes. Pairing this workflow with an agentic optimization loop allowed the system to autonomously identify catalytic-site targeting strategies. Under a fixed compute budget, a human-in-the-loop (HITL) workflow raised the computational hit rate from 5.06% to 9.33% while further cutting GPU hours by ~ 42%. We also found that omitting target multiple sequence alignments during refolding roughly substantially increased the apparent yield. Wet-lab validation with yeast display identified nanomolar binders from the generated designs with the HITL and the fully autonomous agent (human-out-of-the-loop, HOOTL) arms recovering more enriched designs than the PI-alone baseline. Together, target excision and agent-guided search offer a practical way to scale de novo binder design to large, therapeutically relevant proteins.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Jun W. Kim, Artiom Myaskovsky, Oscar Donosa, Lawrence Chan, Jamie Rogers, Avinatan Hassidim, Yossi Matias, Annalisa Pawlosky. 2026-10-23. Agent-guided epitope excision enables economical de novo binder design. https://arxiv.org/abs/2610.33195

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related papers

mdRNAcat: A Molecular Dynamics RNA Catalog of REST2 Conformational Ensembles

Learning molecular models of RNA requires simulation data that capture conformational variability and provide consistent physical training signals. Here, we introduce mdRNAcat, a curated dataset of all-atom molecular dynamics (MD) simulations of 48 RNA systems selected to promote sequence diversity. Each system is simulated using replica-exchange with solute scaling (REST2), with 32 Hamiltonian states and production lengths of 200-300 ns per state. The dataset provides atomic coordinates, instantaneous forces, and forces reevaluated under the unscaled reference Hamiltonian, together with structural annotations and replica-exchange metadata. Coordinates and forces are available at 1 ps intervals for the reference state and 100 ps intervals across all states in a standardized HDF5 format. We characterize conformational sampling, exchange behavior, base pairing, and sugar-pucker distributions to document the properties of the simulated ensembles. mdRNAcat provides a reusable resource for developing and evaluating data-driven RNA models, including coarse-grained force fields.

q-bio.BM↗

MechGate: combining mechanism-derived measures of permeation and efflux to screen small molecule drugs targeting Escherichia coli

Most antibiotic molecules must cross the cell membrane and escape efflux pumps before hitting their targets. For de novo antibiotic design, very few of the in-silico-generated drug molecules can successfully pass these two steps. Existing evaluations of generated molecules do not separate these steps. Therefore, we introduce MechGate, a mechanism-resolved screening tool evaluating small drug molecules against E. coli, measuring permeation, efflux and antibacterial activity. After SMILES input, five measures are reported side by side: two for permeation via porins, one for permeation via the phospholipid membrane, one for efflux and one for activity. Each measure is read on its own, so a molecule that fails can be traced to the step that stops it. All features are taken from papers that state their mechanism rather than selected by importance ranking. On an external set of marketed antibacterials the measures give a precision of 0.789 to 0.873 against baselines near 0.44, and combining them the way the mechanism predicts raises precision to 0.92. We also find that the four public source libraries are separable from one another using physicochemical features alone; every measure here therefore draws both classes from a single library. All code is open-source and requires no commercial software.

q-bio.BM↗

Computational De Novo Design of Miniprotein Candidate Neutralizers Targeting the IL-23 Cytokine Subunit p19

Interleukin-23 (IL-23) drives T-helper-17 inflammation underlying inflammatory bowel disease and psoriasis; anti-p19 antibodies are clinically effective but large, costly, and injectable. De novo miniproteins are an attractive alternative, yet published designs target the IL-23 receptor; the IL-23 cytokine itself has not been addressed. A further obstacle is that the standard confidence score (ipTM) tracks construct length rather than interface quality. We computationally design miniprotein binders against the IL-23R-binding face of p19 (PDB 3DUH) and score every design with ipSAE, a length-robust interface metric derived from AlphaFold-initial-guess predicted aligned error. A conventional RFdiffusion/ProteinMPNN/ColabFold pipeline yields no reliable predicted interface across 972 designs (best ipSAE 0.30), and a scoring artifact, in which single-sequence ColabFold under-rates binder pLDDT by approximately 56 points, explains an earlier misleading "binders do not fold" signal. An interface-optimized hallucination method (BindCraft), scored identically, yields 42 of 50 designs above ipSAE 0.60 (best 0.804). An AlphaFold-independent geometric check reproduces the conventional failure: no top-ranked conventional design reaches the buried area or interface hydrogen-bond count of the weakest lead. Five all-alpha-helical leads (72-104 residues) collectively engage all six targeted hotspots; two dock within the intact p40/p19 heterodimer and all show favorable Rosetta energetics. A p40-alone counter-screen returns ipSAE 0.00 for all five, indicating no spurious p40 interface. To our knowledge, these are the first computationally proposed de novo miniprotein candidates designed to occlude the IL-23R-binding face of IL-23 p19. All results require experimental validation.

q-bio.BM↗